Answers are grounded in this paper and cite their sources.
ACCC: ACCCNow in its 14th year, the Association of Cancer Care Centers (ACCC) Innovator Award program recognizes visionary and compelling ideas in oncology from cancer program members nationwide. Innovations advance the goal(s) of improving access, quality, and value in cancer care delivery. Applications are peer-reviewed and winners are selected by a task force of ACCC members. In 2024, ACCC honored these six forward-thinking programs, which will present their innovations at the ACCC 41st National Oncology Conference to be held October 9-11, 2024, in Minneapolis, MN. Creating a Community-Wide Safety Net for Centralized Tracking and Management of Incidental Lung Nodule Findings. Globally, cancer cases are predicted to increase 77 percent by 2050.1 While the disease poses significant challenges, there is a powerful weapon in our arsenal: early detection. When cancer can be identified in Stage I or II, there is a much greater opportunity to improve patient outcomes and save lives. Few organizations realize one of the greatest levers for identifying potential cancer is right within their four walls. Annually, hospitals conduct over 691 million scans and reveal a substantial number of potentially cancerous abnormalities that were not the primary reason for the imaging.2 Incidental findings are present in 40 percent of all radiology scans performed in the United States; one of every 20 abnormalities is classified as high risk.2 The University of Colorado Cancer Center in Aurora is using enterprise intelligence software to analyze imaging results of all patients treated in its health care system to identify and stratify those with high-risk findings. Patients and providers are alerted about abnormal results, and patients are referred for additional follow-up. This system-wide approach led to a 2,514 percent increase in actively managed patients, and implementation of a centralized care management function has streamlined processes and has reduced the time to recommended next steps from 34 to 5 days. Leveraging the EHR to Automate Biosimilar Selection and Streamline the Prior Authorization Process. Biosimilars have gained significant market share in many therapeutic areas where they have been introduced. It is estimated that from 2017 to 2026, use of biosimilars by the U.S. health system may save $54 billion.3 One of the primary challenges associated with the increased use of biosimilars is the complex prior authorization and step therapy process for commercial payers. To address this challenge, Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, OH, developed a rule-based informatics solution. Pulling information from the electronic health record (EHR), the e-tool automates the election of an appropriate biosimilar therapy based on the patient's insurance and hospital formulary preferences and streamlines the prior authorization and approval processes. Implementation of this technology has lessened the administrative burden of providers, pharmacists, and prior authorization specialists and increased the use of biosimilars by 21.9 percent. A One-Stop Breast Clinic Improves Time to Diagnosis and Patient Satisfaction. Modeled after the original One Stop Breast Clinic at the Gustav Roussy Institute in France, St. Luke's University Health Network in Easton, PA, was the first facility in the United States to introduce this clinical pathway. The One Stop Breast Clinic is an approach to rapid diagnosis for patients with concerning breast symptoms, such as a lump, asymmetry, breast pain, nipple discharge, or call-backs from screening mammogram. It's intended to reduce the turnaround time from 6 to 8 days to 48 hours or less for results from imaging, pathology, and other testing. Staff appreciate the One Stop pathway, as it reduces patient anxiety around the process and supports the patient diagnostic journey in a very intentional way. St. Luke's has found that about 60 percent of its One Stop patients have malignant pathology results—a much higher percentage than its average positive predictive value of 32 percent. This high percentage is attributed to effective identification of high-risk patients and the use of contrast-enhanced mammography to confirm a suspicious area or rule out the probability of malignancy. For patients, faster diagnosis means expedited navigation to surgical intervention or treatment.FigureSmart-Texting to High-Risk Patients After Chemotherapy Reduces ED Visits. The Centers for Medicare & Medicaid Services has implemented several programs to reduce emergency department (ED) encounters and inpatient hospital admissions (IPAs). Its OP-35 quality measure added to the Outpatient Quality Reporting Program went into effect on January 1, 2020. This program monitors the rate of ED visits and IPAs within 30 days of hospital-based outpatient chemotherapy treatment. After a retrospective review of its electronic health records identified risk factors associated with ED visits and IPAs, Mercy Oncology Services in St. Louis, MO, developed protocols to proactively address these risk factors and reduce ED visits and IPAs. The cancer program won a 2020 ACCC Innovator Award for this work. Mercy's model has been further refined. The cancer program now uses the Chen model, which is named after a data scientist at the facility who developed the extremely accurate, machine-learning algorithm before losing her own battle with cancer. The Chen model runs each night linked to a smart-texting application that sends texts to patients at 9:00 a.m. each morning for 7 days following chemotherapy to ask about symptoms like diarrhea, fever, nausea, vomiting, and pain. Patients who report severe or worsening symptoms have the smart texting escalated to the oncology clinic where they received their chemotherapy. Across the health system, about 30 responders (patients receiving smart texts) are added every day. Use of this program has helped decrease ED visits to 5.7 percent for responders compared to 6.7 percent for non-responders. The Chen model coupled with AI-enabled smart text platform is allowing Mercy to focus its resources on the highest-risk patients and reduce ED visits and IPAs. A Sustainable Model of Improved Quality for Pancreatic Cyst Surveillance & Early Pancreatic Cancer Detection. Pancreatic cancer presents unique challenges due to its asymptomatic nature. Mucinous pancreatic cysts are the most common identifiable precursor to pancreatic cancer, yet there are no established screening protocols for these cysts as there are for growths involving the lung or breast. It is published that 15 percent or more of the population may harbor a pancreatic cyst.4 Challenges related to care for patients with pancreatic cysts start with the initial scan, as most are incidentally identified. Further, most patients are never referred for surveillance. Recognizing the critical need for early detection of mucinous pancreatic cysts for pancreatic cancer, Cooperman Barnabas Medical Center in Livingston, NJ, collaborated with RWJBarnabas Health and the Rutgers Cancer Institute of New Jersey in New Brunswick to find a new way to manage these malignancies. Specifically, these health care organizations worked with an AI company to develop the first-of-its-kind model for identifying and monitoring pancreatic abnormalities. The patient management software integrates with the electronic health record and facilitates patient identification, risk assessment, care plan setting, care plan tracking, patient and provider communication, outcome recording, and registry functionality.FigureUsing a computational linguistics data model, the AI solution can identify and capture pancreatic abnormalities from radiology reports with 98 percent accuracy on multiple radiology modalities, including CT, MRI, PET, and ultrasound. Over the first 2 years, 82 pancreatic cancers were detected from incidental findings, and 65 percent of patients were diagnosed in earlier stages (I, II, and III). These findings underscore the critical importance that incidental finding programs have on saving lives through early detection and intervention. Implementation of a Bispecific T-Cell Engager Therapy Program at a Community Cancer Center. Until recently, patients at Corewell Health in northern Michigan who needed bispecific T-cell engager (BiTE) therapies had to travel 141 miles to Grand Rapids, MI, or as far as 663 miles to the Mayo Clinic in Rochester, MN. Indeed, for many patients, travel costs alone eliminated that treatment option. Patients who could afford to drive 3-10 hours to receive treatment still had to be established with a new care team. Further, they often were isolated from their family and local support systems. A team of clinical oncology pharmacists at the Cowell Family Cancer Center in Traverse City, MI, developed and implemented a program that would allow patients in northern Michigan to receive BiTE therapies in the communities where they live and work. Delivery of this cutting-edge treatment in the community setting required development of policies and protocols, management of toxicities, creation of patient education, design of scoring and charting tools for nursing staff, and implementation of a monitoring system to transition patients from inpatient to outpatient care. The last step accomplished by a team of clinical pharmacists was to conduct interprofessional training and education. In addition to these ACCC Innovator Award Winner sessions, other conference highlights include: A 4-hour pre-conference jointly hosted by the American Cancer Society and the Academy of Oncology Nurse & Patient Navigators on “Building Sustainable Navigation.” A 2-hour accredited training session by the American College of Healthcare Executives on “Leveraging Governance and Partnerships to Advance Health Equity.” A session track dedicated to the 2024-2025 ACCC President's theme, Reimagining Community Engagement and Equity in Cancer. An international panel discussion, “Come Together: A Global Perspective on Cancer Care Delivery,” with clinician representatives from Africa, Australia, Central and South America, Europe, and the Middle East. Connect With ACCC Register for the meeting: accc-cancer.org/NOC Learn about membership: [email protected]
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: